C-TIL051 + NKTR-255 + pembrolizumab

C-TIL051 + NKTR-255 + pembrolizumab is an **investigational combination therapy** composed of three separate components designed for cancer immunotherapy. - **C-TIL051** is an investigational tumor-infiltrating lymphocyte (TIL) cell therapy, potentially derived from patients’ own tumor tissue, intended to reconstitute and expand autologous tumor-specific T cells for reinfusion. - **NKTR-255** is a recombinant human interleukin-15 (IL-15) agonist, intended to stimulate and prolong the survival and proliferation of natural killer (NK) and CD8+ T cells. - **Pembrolizumab** is a programmed death receptor-1 (PD-1)-blocking monoclonal antibody (brand name: Keytruda), approved for multiple cancer indications, and acts as an immune checkpoint inhibitor enhancing anti-tumor T-cell response[2][5][8]. The rationale of this triplet combination is to augment anti-tumor immune response by (1) expanding tumor-reactive lymphocytes (C-TIL051), (2) increasing lymphocyte activity and persistence (NKTR-255), and (3) blocking inhibitory immune signaling (pembrolizumab). This combination is under investigation primarily for solid tumors, with a particular focus on melanoma and other difficult-to-treat or refractory cancers.

Other names

NKTR-255NKTR255NKTR 255C-TIL051C-TIL-051C-TIL 051pembrolizumab